|
1
|
Pennisi F, Borlini S, Harrison H,
Cuciniello R, D'Amelio AC, Barclay M, Ricciardi GE, Lyratzopoulos G
and Renzi C: Cancer risk prediction using machine learning for
supporting early cancer diagnosis in symptomatic patients: A
systematic review of model types. Cancer Med.
14(e71463)2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sherman RE, Anderson SA, Dal Pan GJ, Gray
GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb
MA, et al: Real-world evidence-what is it and what can it tell us?
N Engl J Med. 375:2293–2297. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Duan R, Luo C, Schuemie MJ, Tong J, Liang
CJ, Chang HH, Boland MR, Bian J, Xu H, Holmes JH, et al: Learning
from local to global: An efficient distributed algorithm for
modeling time-to-event data. J Am Med Inform Assoc. 27:1028–1036.
2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ganti AK, Klein AB, Cotarla I, Seal B and
Chou E: Update of incidence, prevalence, survival, and initial
treatment in patients with non-small cell lung cancer in the US.
JAMA Oncol. 7:1824–1832. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Jones GS and Baldwin DR: Recent advances
in the management of lung cancer. Clin Med (Lond). 18 (Suppl
2):s41–s46. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Delmonte A, Gentili N, Roncadori A,
Maltoni R, Danesi V, Hindocha P, Leal C, Oikonomou S, Mella M,
Lay-Flurrie S, et al: Real-world treatment patterns and survival in
patients with advanced non-small cell lung cancer: An Italian
retrospective cohort study. Cancers (Basel). 18(538)2026.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rajan A, Kim C, Heery CR, Guha U and
Gulley JL: Nivolumab, anti-programmed death-1 (PD-1) monoclonal
antibody immunotherapy: Role in advanced cancers. Hum Vaccin
Immunother. 12:2219–2231. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chen X, Yang M, Huang Y, Tu J, Cai Y and
Yuan X: Molecular mechanisms underlying the abscopal effect induced
by radiotherapy and its synergistic translational potential with
immunotherapy. Ther Adv Med Oncol.
17(17588359251387534)2025.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Laurent PA, Shi L, Bouarroudj L, Benzazon
N, Gerbé De Thoré M, Liu W, Aglave M, Bergeron P, Naulin F,
Sitterlé L, et al: Low-dose radiotherapy enhances the efficacy of
PD-L1 blockade and induces the abscopal effect. J Immunother
Cancer. 13(e011487)2025.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mariniello A, Borgeaud M, Weiner M,
Frisone D, Kim F and Addeo A: Primary and acquired resistance to
ımmunotherapy with checkpoint ınhibitors in NSCLC: From bedside to
bench and back. BioDrugs. 39:215–235. 2025.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Asano Y, Hayashi K, Miwa S, Taniguchi Y,
Okuda M, Matsumoto I, Yano S and Demura S: Combination of immune
checkpoint inhibitors and radiotherapy for bone metastases induces
an abscopal effect and improves outcomes in non-small cell lung
cancer. Oncol Lett. 30(524)2025.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Li G, Liu C, Xi P, Hou L, Xia Y, Qi Y, Pan
W, Bai W, Li X, Zhou H, et al: Neoadjuvant immunotherapy plus
chemotherapy in locally advanced stage III NSCLC patients
undergoing definitive chemo-radiotherapy-a real-world multicenter
retrospective study. Lung Cancer. 211(108883)2026.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fiorica F, Tebano U, Gabbani M, Perrone M,
Missiroli S, Berretta M, Giuliani J, Bonetti A, Remo A, Pigozzi E,
et al: Beyond abscopal effect: A meta-analysis of ımmune checkpoint
ınhibitors and radiotherapy in advanced non-small cell lung cancer.
Cancers (Basel). 13(2352)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Spigel DR, Faivre-Finn C, Gray JE, Vicente
D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R,
Quantin X, et al: Five-year survival outcomes from the PACIFIC
trial: Durvalumab after chemoradiotherapy in stage III
non-small-cell lung cancer. J Clin Oncol. 40:1301–1311.
2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et
al: Durvalumab after chemoradiotherapy in stage III non-small-cell
lung cancer. N Engl J Med. 377:1919–1929. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Peters S, Salomonsen RJB, Diaz Perez I,
Shcherbakova T, Wang A, Cai L, Sadow S and Liu SV: Real-world
outcomes versus clinical trial results of first-line immunotherapy
with or without chemotherapy in patients with metastatic
non-small-cell lung cancer: The CORRELATE study. ESMO Open.
11(106031)2026.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kim K, Sweeting M, Jönsson L and Wilking
N: Long-term real-world survival of ımmunotherapy compared to
chemotherapy for metastatic nonsmall cell lung cancer: A propensity
score-matched analysis. Thorac Cancer. 16(e15535)2025.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Muscaritoli M, Arends J, Bachmann P,
Baracos V, Barthelemy N, Bertz H, Bozzetti F, Hütterer E, Isenring
E, Kaasa S, et al: ESPEN practical guideline: Clinical nutrition in
cancer. Clin Nutr. 40:2898–2913. 2021.PubMed/NCBI View Article : Google Scholar
|
